Is the 9-valent HPV vaccine significantly better than the 4-valent one?

       The 9-valent HPV vaccine offers broader protection than the 4-valent vaccine, with several key differences—including the range of diseases prevented, the recommended age groups for vaccination, and the nature of potential side effects. Details are as follows:

       1. Differences in Diseases Prevented

       The 4-valent vaccine provides substantial protection against cervical cancer and genital warts. In contrast, the 9-valent vaccine not only protects against cervical cancer and genital warts but also helps prevent vaginal cancer, anal cancer, and other related cancers—thus offering broader disease coverage.

       2. Differences in Recommended Age Groups

       Both the 9-valent and 4-valent vaccines are approved for individuals aged 9 years and older. Vaccination prior to initiation of sexual activity generally yields optimal preventive efficacy. However, individuals who have already become sexually active—but have not yet been infected with HPV—may still benefit from vaccination. Additionally, the 4-valent vaccine is indicated for individuals aged 20–45 years, whereas the 9-valent vaccine is approved for those aged 16–26 years. Therefore, individuals should select the appropriate vaccine based on their age.

       3. Differences in Side Effects

       All vaccines carry a potential risk of side effects. Following administration of the 9-valent vaccine, mild local reactions—such as swelling at the injection site—may occur. These reactions are typically mild, transient, and resolve spontaneously without intervention.